Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.

Abstract

The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy. A total of 155 patients were treated with 400 mg lomefloxacin once daily for 15 days while a total of 139 patients received 500 mg of ciprofloxacin twice daily for 15 days. Eradication of the initial pathogen was observed in 87% of patients treated with lomefloxacin and in 81% of ciprofloxacin-treated patients while clinical success was achieved in 85% of lomefloxacin-treated patients and in 76% of patients treated with ciprofloxacin. The differences in outcome between the two treatment groups were not statistically significant (chi 2 = ns). Both drug regimens were well tolerated and no patients discontinued treatment due to adverse events. In conclusion, once-daily lomefloxacin was as effective as twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.

• Authors: E Pisani, R Bartoletti, A Trinchieri, M Rizzo
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 8 Issue 3 Pg. 210-3 (Jun 1996) ISSN: 1120-009X [Print] England
• PMID: 8808718 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Quinolones
• Ciprofloxacin
• lomefloxacin

Topics

• Administration, Oral
• Adult
• Aged
• Anti-Infective Agents (administration & dosage, pharmacology, therapeutic use)
• Ciprofloxacin (administration & dosage, pharmacology, therapeutic use)
• Escherichia coli (drug effects)
• Female
• Fluoroquinolones
• Humans
• Italy
• Klebsiella (drug effects)
• Male
• Middle Aged
• Proteus (drug effects)
• Pseudomonas (drug effects)
• Quinolones (administration & dosage, pharmacology, therapeutic use)
• Streptococcus (drug effects)
• Treatment Outcome
• Urinary Tract Infections (drug therapy, microbiology)